1873 — VIVA Biotech Holdings Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapSuper Stock

Annual income statement for VIVA Biotech Holdings, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	697	2,104	2,380	2,156	1,987
Cost of Revenue
Gross Profit	305	651	816	738	687
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	443	1,711	2,664	2,209	1,637
Operating Profit	253	393	-285	-53.7	350
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-356	348	-459	-56	296
Provision for Income Taxes
Net Income After Taxes	-379	301	-504	-99.8	222
Minority Interest
Net Income Before Extraordinary Items
Net Income	-387	288	-528	-116	167
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	-387	163	-528	-116	167
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0.243	0.081	-0.259	0.017	0.06
Dividends per Share